This tracker provides regularly updated information on U.S. government funding for global health. It includes historical trends and tracks funding levels throughout the appropriations process. Data can be customized by fiscal year, sector, and U.S. agency.
- view as grid
- view as list
This summary of the Coronavirus Aid, Relief, and Economic Security (CARES) Act highlights and summarizes health-related provisions focused on the COVID-19 outbreak in the United States and support for the global response.
In response to prescription drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing the federal government to negotiate the price of prescription drugs for Medicare and private payers. This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal government the authority to negotiate drug prices in Medicare, describes the negotiation provisions in key legislation (H.R. 3), and discusses the potential spending effects for the federal government, beneficiaries, and private payers.
The U.S. government is the largest donor to global health in the world. This fact sheet breaks down the U.S. global health budget by program area: HIV/PEPFAR; tuberculosis (TB); malaria/the President’s Malaria Initiative (PMI); the Global Fund to Fight AIDS, Tuberculosis, and Malaria; maternal & child health (MCH); nutrition; family planning & reproductive health (FP/RH); global health security; and neglected tropical diseases (NTDs).
This tracker provides a listing of global health-related legislation introduced in the current Congress.
As Congress begins to debate increased assistance for the global response to COVID-19, we look at how current U.S. global COVID-19 emergency funding is being channeled, particularly to countries and regions.